nach oben

Strahlentherapie und Onkologie

Erschienen in:

13.08.2018 | Original Article

Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer

verfasst von: Chai Hong Rim, MD, Sangjoon Park, MD, Joong Yeol Woo, CMD, Jinsil Seong, MD, PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated whether external beam radiotherapy (EBRT) could induce compensatory liver hypertrophy in liver cancers and assessed related clinical factors.

Methods

A total of 82 consecutive patients receiving EBRT for hepatocellular carcinoma (n = 77) or cholangiocarcinoma (n = 5) from April 2012 to June 2014 were recruited and divided into two subgroups according to tumor location in the right or left lobe. The left lateral and right lobes were considered as unirradiated volumes accordingly. Total liver volume (TLV), nontumor liver volume (NLV), left and right lobe whole volume (LLWV and RLWV, respectively), volume of liver irradiated < 30 Gy (V_< ₃₀ _Gy), Child–Pugh (CPS) score, future liver remnant (FLR) ratio, and percentage of FLR hypertrophy from baseline (%FLR) were assessed.

Results

In the right lobe group, %FLR hypertrophy and LLWV increased significantly at all follow-ups (p < 0.001). %FLR hypertrophy steadily increased until the fourth follow-up. Multivariate analysis showed that the factor associated with maximum %FLR hypertrophy was tumor extent (upper or lower lobe vs. both lobes; p = 0.022). Post-RT treatments including transarterial chemoembolization or hepatic arterial infusion chemotherapy were associated with a CPS increase ≥ 2 (p = 0.002). Analysis of the RT only subgroup also showed a significant increase of %FLR until the fourth follow-up (p < 0.001). In the left lobe group, %FLR hypertrophy and RLWV showed no significant changes during follow-up.

Conclusion

Significant compensatory hypertrophy of the liver was observed, with a steady increase of %FLR hypertrophy until the fourth follow-up (median: 396 days). Locally advanced tumors extending across the upper and lower right lobe were a significant factor for compensating hypertrophy after EBRT.

Nur mit Berechtigung zugänglich

National Comprehensive Cancer Network (2016) NCCN Clinical Practice Guidelines in Oncology, Hepatobiliary cancers. https://www.nccn.org/professionals/physician_gls/default_nojava.aspx. Accessed 3 Oct 2016

Klein J, Dawson LA (2013) Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 87(1):22–32CrossRef

Yu SJ (2016) A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol 22(1):7–17CrossRef

Lee HS, Choi GH, Choi JS, Kim KS, Han KH, Seong J et al (2014) Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy. Ann Surg Oncol 21(11):3646–3653CrossRef

Kubo S, Shiomi S, Tanaka H, Shuto T, Takemura S, Mikami S et al (2002) Evaluation of the effect of portal vein embolization on liver function by 99mTc-galactosyl human serum albumin scintigraphy. J Surg Res 107(1):113–118CrossRef

Kudo M, Todo A, Ikekubo K, Yamamoto K, Vera DR, Stadalnik RC (1993) Quantitative assessment of hepatocellular function through in vivo radioreceptor imaging with technetium 99m galactosyl human serum albumin. Hepatology 17(5):814–819PubMed

Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J et al (2008) Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 247(1):49–57CrossRef

Pandanaboyana S, Bell R, Hidalgo E, Toogood G, Prasad KR, Bartlett A et al (2015) A systematic review and meta-analysis of portal vein ligation versus portal vein embolization for elective liver resection. Surgery 157(4):690–698CrossRef

Capussotti L, Muratore A, Baracchi F, Lelong B, Ferrero A, Regge D et al (2008) Portal vein ligation as an efficient method of increasing the future liver remnant volume in the surgical treatment of colorectal metastases. Arch Surg 143(10):978–982CrossRef

10.

Zhang G‑Q, Zhang Z‑W, Lau W‑Y, Chen X‑P (2014) Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): a new strategy to increase resectability in liver surgery. Int J Surg 12(5):437–441CrossRef

11.

Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK et al (2013) Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 59(5):1029–1036CrossRef

12.

Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF et al (2009) Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 16(6):1587–1596CrossRef

13.

Tokuuye K, Sumi M, Kagami Y, Murayama S, Kawashima M, Ikeda H et al (2000) Radiotherapy for hepatocellular carcinoma. Strahlenther Onkol 176(9):406–410CrossRef

14.

Korean Liver Cancer Study Group, National Cancer Center (2015) 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 16(3):465–522CrossRef

15.

Rim CH, Seong J (2016) Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J 34(3):160–167CrossRef

16.

Park HC, Yu JI, Cheng JCH, Zeng ZC, Hong JH, Wang MLC et al (2016) Consensus for radiotherapy in hepatocellular carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): current practice and future clinical trials. Liver Cancer 5(3):162–174CrossRef

17.

Kim TH, Kim DY, Park JW, Kim SH, Choi JI, Kim HB et al (2007) Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 67(1):225–231CrossRef

18.

Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60CrossRef

19.

Shindoh J, Vauthey JN, Zimmitti G, Curley SA, Huang SY, Mahvash A et al (2013) Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume. J Am Coll Surg 217(1):126–133 (Including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach)CrossRef

20.

Zhang GQ, Zhang ZW, Lau WY, Chen XP (2014) Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): a new strategy to increase resectability in liver surgery. Int J Surg 12(5):437–441CrossRef

21.

Imada H, Kato H, Yasuda S, Yamada S, Yanagi T, Hara R et al (2010) Compensatory enlargement of the liver after treatment of hepatocellular carcinoma with carbon ion radiotherapy—relation to prognosis and liver function. Radiother Oncol 96(2):236–242CrossRef

22.

May BJ, Madoff DC (2012) Portal vein embolization: rationale, technique, and current application. Semin Intervent Radiol 29(2):81–89CrossRef

23.

Abdalla EK, Denys A, Chevalier P, Nemr RA, Vauthey JN (2004) Total and segmental liver volume variations: implications for liver surgery. Surgery 135(4):404–410CrossRef

24.

Kim RD, Kim JS, Watanabe G, Mohuczy D, Behrns KE (2008) Liver regeneration and the atrophy-hypertrophy complex. Semin Intervent Radiol 25(2):92–103CrossRef

25.

de Baere T, Teriitehau C, Deschamps F, Catherine L, Rao P, Hakime A et al (2010) Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization. Ann Surg Oncol 17(8):2081–2089CrossRef

26.

Nagino M, Ando M, Kamiya J, Uesaka K, Sano T, Nimura Y (2001) Liver regeneration after major hepatectomy for biliary cancer. Br J Surg 88(8):1084–1091CrossRef

27.

Tani M, Tomiya T, Yamada S, Hayashi S, Yahata K, Tamura Y et al (1994) Regulating factors of liver regeneration after hepatectomy. Cancer Chemother Pharmacol 33:S29–S32CrossRef

28.

Denecke T, Seehofer D, Steffen IG, Grieser C, Stelter L, Schnapauff D et al (2011) Arterial versus portal venous embolization for induction of hepatic hypertrophy before extended right hemihepatectomy in hilar cholangiocarcinomas: a prospective randomized study. J Vasc Interv Radiol 22(9):1254–1262CrossRef

29.

Vogl TJ, Balzer JO, Dette K, Hintze R, Pegios W, Maurer J et al (1998) Initially unresectable hilar cholangiocarcinoma: Hepatic regeneration after transarterial embolization. Radiology 208(1):217–222CrossRef

30.

Yamakado K, Takeda K, Matsumura K, Nakatsuka A, Hirano T, Kato N et al (1997) Regeneration of the un-embolized liver parenchyma following portal vein embolization. J Hepatol 27(5):871–880CrossRef

31.

Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y et al (2004) Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 139(7):766–774CrossRef

32.

Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V (2006) Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg 93(9):1091–1098CrossRef

Titel: Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer
verfasst von: Chai Hong Rim, MD
Sangjoon Park, MD
Joong Yeol Woo, CMD
Jinsil Seong, MD, PhD
Publikationsdatum: 13.08.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 11/2018
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1342-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Age-corrected hearing loss after chemoradiation in cervical cancer patients

Evolution of adjuvant treatment in endometrial cancer—no evidence and new questions?

Adenocarcinoma of the oesophagus: neoadjuvant chemoradiation and radical surgery

Cost analysis of a wait-and-see strategy after radiochemotherapy in distal rectal cancer

The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer

Accuracy assessment of a potential clinical use of navigation-guided intra-operative liver metastasis brachytherapy—a planning study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie